RJA
HURA

Raymond James & Associates’s TuHURA Biosciences HURA Stock Holding History

Raymond James & Associates’s Portfolio HURA Stock Details HURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9
Closed -$6K – 4251
2022
Q1 		$6K Hold
9
– – ﹤0.01% 4087
2021
Q4 		$8K Hold
9
– – ﹤0.01% 4084
2021
Q3 		$14K Hold
9
– – ﹤0.01% 4037
2021
Q2 		$36K Hold
9
– – ﹤0.01% 3943
2021
Q1 		$27K Buy
+9
New +$30.6K ﹤0.01% 3900

Other funds holding HURA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's HURA Position: Q2 2022 in Review

Raymond James & Associates sold out of TuHURA Biosciences (HURA) in Q2 2022, closing a stake of 9 shares — an estimated $6K sold.

Raymond James & Associates first reported a position in HURA in Q1 2021 and held it in 5 quarters. The position peaked at $36K in Q2 2021. 20 funds tracked by Wall St. Rank hold HURA as of Q2 2022.

  • Raymond James & Associates reported no remaining TuHURA Biosciences position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 9 TuHURA Biosciences shares in Q2 2022, an estimated $6K.
  • Raymond James & Associates first reported a position in TuHURA Biosciences in Q1 2021 and held it in 5 quarters.
  • Raymond James & Associates's TuHURA Biosciences position peaked at $36K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.